Food Effect Study With BMS-955176
An Open-Label, Randomized, Crossover Adaptive Design Study to Assess the Effect of Food on the Pharmacokinetics of BMS-955176 Administered as a Micronized Crystalline Tablet in Healthy Subjects
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Primary Purpose
Other: This study will assess the impact of a light meal, a standard meal, and a high fat meal on the pharmacokinetics (PK) of BMS-955176 micronized crystalline (MC) tablet at a dose of 180 mg relative to fasted conditions.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Nottinghamshire
-
Ruddington Fields, Nottinghamshire, Det Forenede Kongerige, NG11 6JS
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examinations, vital sign measurements, 12-lead ECG measurements, and clinical laboratory test results
- Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg)/[Height (m)]2
- Men and women, ages 18 to 50 years, inclusive
- Women must not be of childbearing potential, must not be breastfeeding
Exclusion Criteria:
- Any significant acute or chronic medical illness
- History of cardiac disease or clinically significant cardiac arrhythmias
- Current or recent (within 3 months of study drug administration) gastrointestinal disease
- Any major surgery within 4 weeks of study drug administration
- Any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm 1 (ABDC): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 2 (BCAD): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 3 (CDBA): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 4 (DACB): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 5 (EFHG): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 6 (FGEH): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 7 (GHFE): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 8 (HEGF): BMS-955176
BMS-955176 single dose by mouth for each treatment as specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 9 (IJK): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 10 (JKI): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 11 (KIJ): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 12 (IKJ): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 13 (JIK): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 14 (KJI): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 15 (LMN): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 16 (OPQ): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 17 (PQO): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 18 (QOP): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 19 (OQP): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 20 (POQ): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
|
Eksperimentel: Arm 21 (QPO): BMS-955176
BMS-955176 single dose by mouth for each treatment specified
|
Single dose by mouth for each treatment specified
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Maximum observed plasma concentration (Cmax) for BMS-955176
Tidsramme: Up to Day 4 of Period 4
|
Up to Day 4 of Period 4
|
|
Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] for BMS-955176
Tidsramme: Up to Day 4 of Period 4
|
Up to Day 4 of Period 4
|
|
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] for BMS-955176
Tidsramme: Up to Day 4 of Period 4
|
Up to Day 4 of Period 4
|
|
Plasma concentration at 24 hours post-dose (C24) for BMS-955176
Tidsramme: Up to Day 4 of Period 4
|
Up to Day 4 of Period 4
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability
Tidsramme: Up to 30 days post discontinuation of dosing
|
Safety and tolerability measured by incidence of AEs, serious AEs (SAEs), AEs leading to discontinuation and death, marked abnormalities in clinical laboratory tests, viral sign measurements, ECGs, and physical examination Adverse Events (AEs), Electrocardiogram (ECG)
|
Up to 30 days post discontinuation of dosing
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- Langsomme virussygdomme
- HIV-infektioner
- Erhvervet immundefektsyndrom
- Anti-infektionsmidler
- Antivirale midler
- Anti-HIV-midler
- Anti-retrovirale midler
- BMS-955176
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 206221
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .